At Venn Therapeutics, we are developing a pipeline of novel, best-in-class agents that precisely target key mechanisms of cancer and fibrosis. 

  • VTX-001 is a monoclonal antibody that selectively targets integrin αvβ8 and has shown single-agent activity in multiple cancer models. VTX-001 safely blocks TGF-β1 and TGF-β3, completely avoiding blockage of TGF-β2; the blockage of TGF-β2 is associated with cardiac toxicity

  • VTX-001DX is a proprietary companion diagnostic that measures αvβ8 expression

  • VTX-002 is a potent humanized monoclonal antibody with dual targeting of αvβ6 and αvβ8 integrins. The role of αvβ6 and αvβ8 together is critical for fibrosis

  • VTX-003 is a monoclonal antibody currently in discovery that targets integrin αvβ1. αvβ1 is highly expressed on activated fibroblasts, directly binds to the latency-associated peptide of transforming growth factor–β1 (TGF-β1) and mediates TGF-β1 activation

Venn Therapeutics

3802 Spectrum Boulevard 

Suite 146

Tampa, FL 33612

  • LinkedIn
  • Twitter

© 2020 by Venn Therapeutics